JP2014515762A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515762A5 JP2014515762A5 JP2014509281A JP2014509281A JP2014515762A5 JP 2014515762 A5 JP2014515762 A5 JP 2014515762A5 JP 2014509281 A JP2014509281 A JP 2014509281A JP 2014509281 A JP2014509281 A JP 2014509281A JP 2014515762 A5 JP2014515762 A5 JP 2014515762A5
- Authority
- JP
- Japan
- Prior art keywords
- conjugate
- occurrence
- independently
- amino acid
- carrier peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/101,942 US20110269665A1 (en) | 2009-06-26 | 2011-05-05 | Compound and method for treating myotonic dystrophy |
| US13/101,942 | 2011-05-05 | ||
| US13/107,528 US9238042B2 (en) | 2010-05-13 | 2011-05-13 | Antisense modulation of interleukins 17 and 23 signaling |
| US13/107,528 | 2011-05-13 | ||
| PCT/US2011/061282 WO2012150960A1 (en) | 2011-05-05 | 2011-11-17 | Peptide oligonucleotide conjugates |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016151179A Division JP2016185991A (ja) | 2011-05-05 | 2016-08-01 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2018108772A Division JP2018135396A (ja) | 2011-05-05 | 2018-06-06 | ペプチドオリゴヌクレオチドコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515762A JP2014515762A (ja) | 2014-07-03 |
| JP2014515762A5 true JP2014515762A5 (hr) | 2015-01-29 |
| JP6478632B2 JP6478632B2 (ja) | 2019-03-06 |
Family
ID=45218873
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509281A Active JP6478632B2 (ja) | 2011-05-05 | 2011-11-17 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2016151179A Pending JP2016185991A (ja) | 2011-05-05 | 2016-08-01 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2018108772A Withdrawn JP2018135396A (ja) | 2011-05-05 | 2018-06-06 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2020070566A Active JP6884250B2 (ja) | 2011-05-05 | 2020-04-09 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2021080358A Pending JP2021113232A (ja) | 2011-05-05 | 2021-05-11 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2024014898A Pending JP2024032974A (ja) | 2011-05-05 | 2024-02-02 | ペプチドオリゴヌクレオチドコンジュゲート |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016151179A Pending JP2016185991A (ja) | 2011-05-05 | 2016-08-01 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2018108772A Withdrawn JP2018135396A (ja) | 2011-05-05 | 2018-06-06 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2020070566A Active JP6884250B2 (ja) | 2011-05-05 | 2020-04-09 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2021080358A Pending JP2021113232A (ja) | 2011-05-05 | 2021-05-11 | ペプチドオリゴヌクレオチドコンジュゲート |
| JP2024014898A Pending JP2024032974A (ja) | 2011-05-05 | 2024-02-02 | ペプチドオリゴヌクレオチドコンジュゲート |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2704749A1 (hr) |
| JP (6) | JP6478632B2 (hr) |
| KR (3) | KR102229650B1 (hr) |
| CN (2) | CN103619356B (hr) |
| AU (5) | AU2011367230B2 (hr) |
| CA (2) | CA2834128A1 (hr) |
| IL (2) | IL273838B (hr) |
| WO (1) | WO2012150960A1 (hr) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE47769E1 (en) | 2004-06-28 | 2019-12-17 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| CA2596506C (en) | 2005-02-09 | 2021-04-06 | Avi Biopharma, Inc. | Antisense composition and method for treating muscle atrophy |
| US20100184833A1 (en) | 2006-08-11 | 2010-07-22 | Prosenta Technologies B.V. | Methods and means for treating dna repeat instability associated genetic disorders |
| US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| AU2008317566B2 (en) | 2007-10-26 | 2014-05-01 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| KR20190079702A (ko) | 2008-10-24 | 2019-07-05 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | Dmd를 위한 다중 엑손 스키핑 조성물 |
| DK2499249T3 (en) | 2009-11-12 | 2018-12-03 | Univ Western Australia | ANTISENCE MOLECULES AND PROCEDURES FOR TREATING PATHOLOGIES |
| TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| JP2015500204A (ja) | 2011-11-18 | 2015-01-05 | サレプタ セラピューティクス， インコーポレイテッド | 機能的に修飾されたオリゴヌクレオチドおよびそのサブユニット |
| ES2727481T3 (es) | 2011-11-30 | 2019-10-16 | Sarepta Therapeutics Inc | Inclusión inducida de exón en atrofia muscular espinal |
| JP6317675B2 (ja) | 2011-11-30 | 2018-04-25 | サレプタ セラピューティクス， インコーポレイテッド | 延長リピート病を処置するためのオリゴヌクレオチド |
| JP6132849B2 (ja) | 2011-12-08 | 2017-05-31 | サレプタ セラピューティクス， インコーポレイテッド | ヒトｌｍｎａを標的とするオリゴヌクレオチド類似体を使用する早老性ラミノパシーを処置するための方法 |
| AU2013212758A1 (en) | 2012-01-27 | 2014-08-14 | Biomarin Technologies B.V. | RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy |
| EP2841578B1 (en) | 2012-04-23 | 2017-06-07 | BioMarin Technologies B.V. | RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders |
| EA201591178A1 (ru) | 2012-12-20 | 2015-11-30 | Сарепта Терапьютикс, Инк. | Улучшенные композиции для пропускания экзона для лечения мышечной дистрофии |
| EP2946013A1 (en) | 2013-01-16 | 2015-11-25 | Iowa State University Research Foundation, Inc. | A deep intronic target for splicing correction on spinal muscular atrophy gene |
| CN117844807A (zh) * | 2013-03-14 | 2024-04-09 | 萨勒普塔医疗公司 | 用于治疗肌营养不良的外显子跳跃组合物 |
| KR20210006516A (ko) * | 2013-03-14 | 2021-01-18 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이영양증의 치료를 위한 엑손 스키핑 조성물 |
| MX2015013117A (es) | 2013-03-15 | 2016-07-14 | Sarepta Therapeutics Inc | Composiciones mejoradas para tratar distrofia muscular. |
| EP3015467A4 (en) * | 2013-05-24 | 2016-11-02 | Ajinomoto Kk | PROCESS FOR THE PRODUCTION OF MORPHOLINO-OLIGONUCLEOTIDE |
| CN105793422B (zh) | 2013-09-05 | 2020-03-03 | 萨罗塔治疗公司(美国) | 酸性α-葡糖苷酶中反义诱导的外显子2纳入 |
| WO2015097600A2 (en) | 2013-12-24 | 2015-07-02 | Sentiss Pharma Private Limited | Topical brimonidine tartrate ophthalmic solution |
| SI3118311T1 (sl) | 2014-03-12 | 2019-05-31 | Nippon Shinyaku Co., Ltd. | Protismiselna nukleinska kislina |
| KR101661277B1 (ko) * | 2014-03-17 | 2016-09-30 | 제주광어주식회사 | 한 개의 뉴크레오타이드 염기 변화를 통한 약독화 바이러스성 출혈패혈증 바이러스 |
| US9790495B2 (en) | 2014-05-16 | 2017-10-17 | Oregon State University | Antisense antibacterial compounds and methods |
| CA2948568A1 (en) | 2014-05-19 | 2015-11-26 | David Greenberg | Antisense antibacterial compounds and methods |
| WO2016040748A1 (en) | 2014-09-12 | 2016-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for detection of smn protein in a subject and treatment of a subject |
| AU2015372560B2 (en) | 2014-12-31 | 2021-12-02 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| CA2977528A1 (en) * | 2015-02-27 | 2016-09-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| US10675356B2 (en) * | 2015-05-19 | 2020-06-09 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| EP3851531A1 (en) | 2015-06-01 | 2021-07-21 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type vii collagen |
| EP3302489A4 (en) | 2015-06-04 | 2019-02-06 | Sarepta Therapeutics, Inc. | METHOD AND COMPOUNDS FOR THE TREATMENT OF DISEASES AND SUFFERING IN CONNECTION WITH LYMPHOCYTES |
| CN108350005B (zh) * | 2015-08-05 | 2024-02-06 | 卫材R&D管理有限公司 | 用于制备均一低聚物的手性试剂 |
| CA2996164A1 (en) * | 2015-08-28 | 2017-03-09 | Sarepta Therapeutics, Inc. | Modified antisense oligomers for exon inclusion in spinal muscular atrophy |
| EP3336098B1 (en) * | 2015-09-10 | 2021-08-11 | IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) | Skin permeable peptide and method for using same |
| CN108699555A (zh) | 2015-10-09 | 2018-10-23 | 萨勒普塔医疗公司 | 用于治疗杜兴肌营养不良和相关病症的组合物和方法 |
| GB2545898B (en) * | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| WO2017112888A1 (en) | 2015-12-23 | 2017-06-29 | David Greenberg | Antisense antibacterial compounds and methods |
| AU2016379399B2 (en) | 2015-12-23 | 2022-12-08 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| AU2017254106B2 (en) | 2016-04-18 | 2024-07-11 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
| CN109477109B (zh) | 2016-04-29 | 2022-09-23 | 萨勒普塔医疗公司 | 靶向人lmna的寡核苷酸类似物 |
| SG11201809502YA (en) * | 2016-05-24 | 2018-12-28 | Sarepta Therapeutics Inc | Processes for preparing phosphorodiamidate morpholino oligomers |
| MX2018016052A (es) * | 2016-06-30 | 2019-05-02 | Sarepta Therapeutics Inc | Oligomeros de omision de exon para distrofia muscular. |
| KR102639633B1 (ko) * | 2016-12-19 | 2024-02-26 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| MX2019006879A (es) | 2016-12-19 | 2019-08-01 | Sarepta Therapeutics Inc | Conjugados de oligomeros de omision de exon para distrofia muscular. |
| KR102552428B1 (ko) * | 2016-12-19 | 2023-07-06 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체 |
| TW201919682A (zh) | 2017-08-08 | 2019-06-01 | 西班牙商阿爾米雷爾有限公司 | 活化Ｎｒｆ２路徑的新穎化合物 |
| EA201991450A1 (ru) * | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
| JP7441455B2 (ja) * | 2017-09-22 | 2024-03-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | 筋ジストロフィーの処置のためのチオモルホリノオリゴヌクレオチド |
| EP3687577A1 (en) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| US20200248178A1 (en) | 2017-09-28 | 2020-08-06 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| US20200254002A1 (en) | 2017-09-28 | 2020-08-13 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
| JP7320500B2 (ja) * | 2017-10-17 | 2023-08-03 | サレプタ セラピューティクス， インコーポレイテッド | アンチセンス送達のための細胞透過性ペプチド |
| EP3697910A4 (en) | 2017-10-18 | 2021-07-14 | Sarepta Therapeutics, Inc. | ANTISENSE OLIGOMERIC COMPOUNDS |
| JP2021521794A (ja) * | 2018-04-26 | 2021-08-30 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーに対するエクソンスキッピングオリゴマーおよびオリゴマーコンジュゲート |
| EP3806868A4 (en) | 2018-06-13 | 2022-06-22 | Sarepta Therapeutics, Inc. | EXON-SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY |
| WO2019241385A2 (en) * | 2018-06-13 | 2019-12-19 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystropy |
| TW202020153A (zh) | 2018-07-27 | 2020-06-01 | 美商薩羅塔治療公司 | 用於肌肉萎縮症之外顯子跳躍寡聚物 |
| WO2020028254A1 (en) * | 2018-07-30 | 2020-02-06 | Sarepta Therapeutics, Inc. | Trimeric peptides for antisense delivery |
| GB201812980D0 (en) * | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| BR112021010982A2 (pt) * | 2018-12-07 | 2021-08-31 | Oxford University Innovation Limited | Ligantes |
| SG11202104960PA (en) | 2018-12-13 | 2021-06-29 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
| GB201821269D0 (en) | 2018-12-28 | 2019-02-13 | Nippon Shinyaku Co Ltd | Myostatin signal inhibitor |
| EP3955966A1 (en) | 2019-04-18 | 2022-02-23 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
| CN110724180B (zh) * | 2019-10-17 | 2021-08-20 | 山东大学 | 一种抑制新生血管生成的多肽及其应用 |
| WO2021132591A1 (ja) | 2019-12-26 | 2021-07-01 | 日本新薬株式会社 | エクソン５０のスキッピングを誘導するアンチセンス核酸 |
| TW202140513A (zh) | 2020-02-22 | 2021-11-01 | 日商Ｊｃｒ製藥股份有限公司 | 人類運鐵蛋白受體結合肽 |
| US20220064638A1 (en) | 2020-02-28 | 2022-03-03 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating smn2 |
| JPWO2021172498A1 (hr) | 2020-02-28 | 2021-09-02 | ||
| US20240024414A1 (en) * | 2020-09-21 | 2024-01-25 | Icahn School Of Medicine At Mount Sinai | Archaea l30 proteins as universal influenza virus therapeutics |
| EP4267191A1 (en) | 2020-12-23 | 2023-11-01 | Sarepta Therapeutics, Inc. | Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy |
| AU2021427595A1 (en) * | 2021-02-12 | 2023-09-28 | Oxford University Innovation Limited | Cell-penetrating peptide conjugates and methods of their use |
| IL307937A (en) | 2021-04-30 | 2023-12-01 | Sarepta Therapeutics Inc | Treatment methods for muscular dystrophy |
| CN117940564A (zh) | 2021-06-23 | 2024-04-26 | 日本新药株式会社 | 反义低聚物的组合 |
| WO2023282344A1 (ja) | 2021-07-08 | 2023-01-12 | 日本新薬株式会社 | 腎毒性軽減剤 |
| CA3225573A1 (en) | 2021-07-08 | 2023-01-12 | Nippon Shinyaku Co., Ltd. | Precipitation suppressing agent |
| WO2023282345A1 (ja) | 2021-07-08 | 2023-01-12 | 日本新薬株式会社 | 腎毒性軽減剤 |
| JPWO2023026994A1 (hr) | 2021-08-21 | 2023-03-02 | ||
| AU2022335128A1 (en) | 2021-08-24 | 2024-03-07 | Jcr Pharmaceuticals Co., Ltd. | Human transferrin receptor-binding antibody-peptide conjugate |
| EP4392558A1 (en) | 2021-09-30 | 2024-07-03 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
| WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
| WO2023178230A1 (en) | 2022-03-17 | 2023-09-21 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
| WO2024064237A2 (en) | 2022-09-21 | 2024-03-28 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
| WO2024097822A1 (en) | 2022-11-02 | 2024-05-10 | Sarepta Therapeutics, Inc. | Formulation of an antisense oligomer conjugate |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| DE3650349T2 (de) | 1985-03-15 | 1995-12-14 | Antivirals Inc | Immunotestmittel für polynukleotid und verfahren. |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| WO1993001286A2 (en) | 1991-06-28 | 1993-01-21 | Massachusetts Institute Of Technology | Localized oligonucleotide therapy |
| EP0656950B1 (en) | 1992-08-21 | 1998-11-04 | Biogen, Inc. | Tat-derived transport polypeptides |
| JPH0915828A (ja) | 1995-07-03 | 1997-01-17 | Fuji Photo Film Co Ltd | 写真処理システム用ペーパーカッター |
| US6245747B1 (en) | 1996-03-12 | 2001-06-12 | The Board Of Regents Of The University Of Nebraska | Targeted site specific antisense oligodeoxynucleotide delivery method |
| CA2291074C (en) | 1997-05-21 | 2008-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
| AU741546B2 (en) * | 1997-07-24 | 2001-12-06 | Perseptive Biosystems, Inc. | Conjugates of transporter peptides and nucleic acid analogs, and their use |
| DE19933492B4 (de) * | 1999-07-16 | 2008-01-10 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung |
| US20020009491A1 (en) | 2000-02-14 | 2002-01-24 | Rothbard Jonathan B. | Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| ATE437647T1 (de) | 2001-02-16 | 2009-08-15 | Cellgate Inc | Transporter mit beabstandeten arginin-teilchen |
| US20030224353A1 (en) | 2001-10-16 | 2003-12-04 | Stein David A. | Antisense antiviral agent and method for treating ssRNA viral infection |
| DK2351844T3 (da) | 2003-04-29 | 2014-09-22 | Sarepta Therapeutics Inc | Præparater til forøgelse af transport- og antisense-effektivitet af nukleinsyreanalog i celler |
| KR100943473B1 (ko) | 2003-08-05 | 2010-02-19 | 에이브이아이 바이오파마 인코포레이티드 | 올리고뉴클레오티드 유사체 및 플라비바이러스 감염을 치료하는 방법 |
| US20050171044A1 (en) | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
| MXPA06012605A (es) * | 2004-05-04 | 2006-12-15 | Nastech Pharm Co | Composiciones y metodos para mejorar el suministro de acidos nucleicos en celulas y para modificar la expresion de genes objetivo en celulas. |
| US20050288246A1 (en) * | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| USRE47769E1 (en) | 2004-06-28 | 2019-12-17 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| US8129352B2 (en) | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
| US8357664B2 (en) | 2004-10-26 | 2013-01-22 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating influenza viral infection |
| US7524829B2 (en) | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
| US7838657B2 (en) | 2004-12-03 | 2010-11-23 | University Of Massachusetts | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
| CA2596506C (en) | 2005-02-09 | 2021-04-06 | Avi Biopharma, Inc. | Antisense composition and method for treating muscle atrophy |
| EP3470072A1 (en) | 2005-06-23 | 2019-04-17 | Biogen MA Inc. | Compositions and methods for modulation of smn2 splicing |
| CA2621964A1 (en) | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
| US8524676B2 (en) | 2005-09-08 | 2013-09-03 | Sarepta Therapeutics, Inc. | Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds |
| EP2002018B1 (en) | 2006-03-07 | 2010-05-12 | AVI BioPharm, Inc. | Antisense antiviral compound and method for treating arenavirus infection |
| SI2024499T1 (en) | 2006-05-10 | 2018-04-30 | Sarepta Therapeutics, Inc. | Analogues of the oligonucleotide, with cationic links between subunits |
| US20100184833A1 (en) | 2006-08-11 | 2010-07-22 | Prosenta Technologies B.V. | Methods and means for treating dna repeat instability associated genetic disorders |
| JP5926475B2 (ja) | 2006-09-21 | 2016-05-25 | ユニバーシティー オブ ロチェスター | 筋緊張性ジストロフィーのためのタンパク質置換治療に関する組成物および方法 |
| JP5227803B2 (ja) | 2006-11-24 | 2013-07-03 | ハイクス ラボラトリーズ合同会社 | スピロキノン化合物及び医薬組成物 |
| WO2009005783A1 (en) * | 2007-06-28 | 2009-01-08 | Blanchette Rockefeller Neurosciences Institute | Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis |
| JP5864100B2 (ja) * | 2007-06-29 | 2016-02-17 | サレプタ セラピューティクス インコーポレイテッド | 組織特異的ペプチドコンジュゲートおよび方法 |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| KR101617472B1 (ko) | 2007-11-15 | 2016-05-02 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 모르폴리노 올리고머의 합성 방법 |
| MX2010006925A (es) * | 2007-12-20 | 2011-05-02 | Angiochem Inc | Conjugados de polipeptido-acido nucleico y sus usos. |
| US20110130346A1 (en) * | 2008-05-30 | 2011-06-02 | Isis Innovation Limited | Peptide conjugates for delvery of biologically active compounds |
| KR20190079702A (ko) * | 2008-10-24 | 2019-07-05 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | Dmd를 위한 다중 엑손 스키핑 조성물 |
| WO2010072228A1 (en) * | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| US20120149757A1 (en) | 2009-04-13 | 2012-06-14 | Krainer Adrian R | Compositions and methods for modulation of smn2 splicing |
| CN116440150A (zh) | 2009-06-17 | 2023-07-18 | 冷泉港实验室 | 用于在对象中调节smn2剪接的组合物和方法 |
| CA3090304A1 (en) * | 2010-05-13 | 2011-11-17 | Sarepta Therapeutics, Inc. | Antisense modulation of interleukins 17 and 23 signaling |
-
2011
- 2011-11-17 EP EP11793913.2A patent/EP2704749A1/en active Pending
- 2011-11-17 AU AU2011367230A patent/AU2011367230B2/en active Active
- 2011-11-17 CA CA2834128A patent/CA2834128A1/en active Pending
- 2011-11-17 IL IL273838A patent/IL273838B/en unknown
- 2011-11-17 CA CA3092114A patent/CA3092114A1/en active Pending
- 2011-11-17 KR KR1020197019623A patent/KR102229650B1/ko active IP Right Grant
- 2011-11-17 KR KR1020217007616A patent/KR102339196B1/ko active IP Right Grant
- 2011-11-17 JP JP2014509281A patent/JP6478632B2/ja active Active
- 2011-11-17 CN CN201180071918.XA patent/CN103619356B/zh active Active
- 2011-11-17 KR KR1020137032241A patent/KR102183273B1/ko active IP Right Grant
- 2011-11-17 WO PCT/US2011/061282 patent/WO2012150960A1/en active Application Filing
- 2011-11-17 CN CN201710707423.0A patent/CN107693797B/zh active Active
-
2013
- 2013-11-04 IL IL229227A patent/IL229227B/en active IP Right Grant
-
2016
- 2016-08-01 JP JP2016151179A patent/JP2016185991A/ja active Pending
-
2017
- 2017-07-18 AU AU2017206179A patent/AU2017206179A1/en not_active Abandoned
-
2018
- 2018-06-06 JP JP2018108772A patent/JP2018135396A/ja not_active Withdrawn
-
2019
- 2019-07-09 AU AU2019204913A patent/AU2019204913A1/en not_active Abandoned
-
2020
- 2020-04-09 JP JP2020070566A patent/JP6884250B2/ja active Active
-
2021
- 2021-04-13 AU AU2021202224A patent/AU2021202224A1/en not_active Abandoned
- 2021-05-11 JP JP2021080358A patent/JP2021113232A/ja active Pending
-
2023
- 2023-05-18 AU AU2023203112A patent/AU2023203112A1/en active Pending
-
2024
- 2024-02-02 JP JP2024014898A patent/JP2024032974A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515762A5 (hr) | ||
| JP2013530154A5 (hr) | ||
| US20200392498A1 (en) | Polynucleotide constructs having bioreversible and non-bioreversible groups | |
| JP2010505741A5 (hr) | ||
| JP2015501817A5 (hr) | ||
| JP2015505839A5 (hr) | ||
| AU2016375869B2 (en) | Biologically active compound conjugated to a stapled or stitched peptide | |
| AU2017354041B2 (en) | Alpha-V beta-6 integrin ligands and uses thereof | |
| JP2011006428A5 (hr) | ||
| AU2016234953A1 (en) | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | |
| RU2015119165A (ru) | Клеточно-реактивные аналоги компстатина, аналоги компстатина длительного действия или аналоги компстатина нацеленного действия, и связанные с ними композиции и способы | |
| JP2010521485A5 (hr) | ||
| JP2019514426A5 (hr) | ||
| AU2012377385A1 (en) | Poly(acrylate) polymers for in vivo nucleic acid delivery | |
| WO2008010463A1 (fr) | Conjugué polymère d'une combrétastatine | |
| MX2013011674A (es) | Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados. | |
| NZ593986A (en) | Compositions comprising a protein and a carrier for topical diagnostic and therapeutic transport | |
| JP2014520120A5 (hr) | ||
| DK2806896T3 (en) | Chitosan covalently bound to small molecule integrin antagonist for targeted delivery | |
| JP2009542582A5 (hr) | ||
| JP2014525939A5 (hr) | ||
| RU2014111179A (ru) | КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ | |
| KR20140127234A (ko) | Ｖｌａ-4 발현 세포로의 표적화된 전달을 위한 인테그린 안타고니스트 접합체 | |
| JPWO2017109494A5 (hr) | ||
| EP4353268A1 (en) | Nanoparticle comprising peptide-lipid conjugate for delivering oligonucleotide into target cell and pharmaceutical composition comprising same |